August 2025 delivered critical clinical practice updates for GLP-1 therapy, including the first generic weight loss approval (Teva’s Saxenda), FDA expansion of Wegovy for liver disease treatment, and major oral formulation breakthroughs from Eli Lilly and Viking Therapeutics. These evidence-based developments provide healthcare providers with new treatment options, expanded patient populations, and enhanced safety protocols that directly impact clinical decision-making.

For GLP‑1 weight loss providers, the latest research, reimbursement changes, and pipeline drugs are redefining how you support patients. This roundup offers concise guidance on preserving lean mass, improving adherence, navigating coverage, and preparing for next‑generation therapies.

GLP-1 trends in June 2025 are redefining obesity treatment—but real-world data reveals more than half of patients quit within a year. This article explores why, what’s coming next, and how providers can adapt to a rapidly changing landscape.

Botox patient satisfaction now defines success in modern aesthetic practice. This guide shows new injectors how to capture feedback, build trust, and grow their business.

Semaglutide is effective for weight loss—but nearly 35% of that loss can be lean muscle. The COURAGE trial from Regeneron explores a novel antibody co-therapy that may protect muscle and improve fat loss outcomes, setting a new bar for obesity treatment.

May 2025 brought conclusive evidence that tirzepatide (Zepbound) produces substantially greater weight loss than semaglutide (Wegovy), with SURMOUNT-5 trial participants losing approximately 20% body weight on tirzepatide versus 14% on semaglutide. Beyond superior weight loss efficacy, GLP-1 medications demonstrated expanded therapeutic benefits for liver disease, cardiovascular health, sleep apnea, and even reduced alcohol consumption, transforming how providers should conceptualize these therapies from ‘weight loss drugs’ to comprehensive metabolic and organ-protective agents.